Coronavirus company news summary – UK approves Moderna’s Covid-19 vaccine – COVAXX starts studying a new vaccine that tackles emerging viral mutations and variants

11 January 2021 (Last Updated January 11th, 2021 09:12)

11 January 2021

Moderna has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Covid-19 Vaccine Moderna, its mRNA vaccine candidate to fight the SARS-CoV-2 virus, under Regulation 174. The authorisation allows the Covid-19 Vaccine Moderna to be supplied to the UK on an emergency and temporary basis.

Humanigen and Eversana have announced a partnership to launch and commercialise Lenzilumab for treating hospitalised and hypoxic Covid-19 patients. However, this would only occur after the US Food and Drug Administration (FDA) has issued an emergency use authorisation (EUA) for the recombinant monoclonal antibody.

Biotech COVAXX has announced it has commenced pre-clinical work, design and testing of a second vaccine candidate to address the recent SARS-CoV-2 viral mutations, and particularly the South African variant.

The FDA of the Philippines has approved Clover Biopharmaceuticals’ clinical trial application for its Covid-19 vaccine in the country. The regulator also stated it has approved a clinical trial for the vaccine developed by Clover Australia. The approval makes Clover the second biopharmaceutical company to have received the go-ahead to conduct Covid-19 vaccine trials in the Philippines.